<DOC>
	<DOCNO>NCT01673893</DOCNO>
	<brief_summary>The purpose registry determine delivery weight adjust , large dose either Abcixmab Eptifibitide ClearWay™ RX , patient admit primary coronary intervention lower readmission rate . This do comparison historical control Medicare/Medicaid readmission database . The registry record use product index procedure , determine whether patient readmitted within 30 day , related index procedure .</brief_summary>
	<brief_title>ClearWay Rx Readmission Registry</brief_title>
	<detailed_description>The primary goal registry prospectively assess delivery weight adjust , bolus either abcixmab eptifibitide ClearWay™ RX patient admit primary PCI lower readmission rate comparison historical control Medicare/Medicaid readmission database . The registry record use product index procedure , ass whether patient readmitted within 30 day , related index procedure . The ClearWay™ RX Local Therapeutic Infusion Catheter micro-porous PTFE balloon catheter design localize infusion various diagnostic therapeutic agent coronary peripheral vasculature . The ClearWay™ RX create low pressure fluid layer surround balloon , allow effective delivery prescribe therapeutic agent , without excessive stress uncontrollable mechanical disruption see traditional elastomeric device . In addition , ClearWay™ RX low pressure irrigate balloon system non-compliant balloon limit amount mechanical stress vessel wall . The objective prospective registry evaluate whether intracoronary ( IC ) delivery Glycoprotein IIb/IIIa inhibitor ( GP IIb/IIIa ) Primary Coronary Intervention ( PCI ) reduce likelihood 30 day readmission result original coronary intervention . Intracoronary delivery GP IIb/IIa inhibitor Abciximab STEMI show reduce myocardial infarct size , reflow slow flow , improve TIMI flow Myocardial Blush Grade2,3 . The ICE trial4 ( N=376 ) compare IC delivery GP IIb/IIa inhibitor Eptifibitide bolus administration , bolus maintenance infusion Eptifibitide , standard intravenous ( IV ) bolus maintenance infusion . At 24 month follow , Major Adverse Coronary Events ( MACE ) rate lower IC bolus group ( 2.5 % ) versus IC bolus maintenance infusion ( 5.8 % ) , IV bolus maintenance infusion ( 10.8 % ) . Further , target lesion revascularization , readmission rate significantly low IC bolus arm , ( 10.9 % versus 16.8 % 28 % respectively ) .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Acute Coronary Syndrome ( STEMI NSTEMI ) patient require use ClearWay™ Rx local therapeutic infusion catheter intracoronary delivery GP IIb/IIIa inhibitor . Patients meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ClearWay</keyword>
	<keyword>Glycoprotein</keyword>
	<keyword>Primary Coronary Intervention</keyword>
	<keyword>Abciximab</keyword>
	<keyword>ST Elevation Myocardial Infarction</keyword>
	<keyword>Non-ST Elevation Myocardial Infarction</keyword>
	<keyword>STEMI</keyword>
	<keyword>NSTEMI</keyword>
	<keyword>Medicare</keyword>
	<keyword>Medicaid</keyword>
	<keyword>Registry</keyword>
	<keyword>catheterization</keyword>
	<keyword>readmission</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>ClearwayRx Catheter</keyword>
</DOC>